Hematologic Oncology | Noopur Raje, MD

Research To Practice | Oncology Videos

Meet The Professors: Key Questions and Emerging Research in the Management of Lymphoma, Chronic Lymphocytic Leukemia and Multiple Myeloma — Part 2: A special video supplement to a CME symposium held at the 2019 ASCO Annual Meeting featuring Dr Raje’s comments on the application of emerging research to patient care:

• Updated risk-stratification model incorporating the revised IMWG diagnostic criteria for smoldering multiple myeloma (MM) (0:00)
• Role of imaging in the monitoring and management of MM (5:07)
• Perspective on the progression-free survival improvement with lenalidomide compared to observation alone for patients with asymptomatic high-risk smoldering MM treated on the Phase III ECOG-E3A06 trial (6:49)
• Results of the Phase III CASSIOPEIA study evaluating the addition of daratumumab to bortezomib/thalidomide/dexamethasone for newly diagnosed MM in patients eligible for autologous stem cell transplant (ASCT) (9:19)
• Emerging data from the Phase III MAIA trial evaluating lenalidomide/dexamethasone (Rd) with or without daratumumab for patients with newly diagnosed MM who are not candidates for ASCT (11:32)
• Role of MRD assessment in clinical decision-making (15:09)
• Results of the Phase III FORTE trial: Efficacy of carfilzomib/Rd (KRd) with or without ASCT for newly diagnosed MM according to risk status (19:31)
• Status of the ongoing Phase III ECOG-E1A11 (ENDURANCE) trial: Bortezomib/Rd versus KRd followed by limited or indefinite maintenance lenalidomide for symptomatic newly diagnosed MM (22:53)
• Clinical experience with and mitigation of differing side effects of bortezomib and carfilzomib (24:29)
• Appropriate use of oral ixazomib as maintenance therapy after ASCT (26:24)
• Dose, duration and tolerability of maintenance lenalidomide (29:49)
• Therapeutic options for patients with MM experiencing disease relapse on maintenance lenalidomide (33:12)
• COLUMBA trial: Efficacy and safety of subcutaneous versus intravenous administration of daratumumab for patients with R/R MM (35:36)
• Similarities and differences between the anti-CD38 antibodies daratumumab and isatuximab (37:47)
• Melflufen: Novel mechanism of action and structural comparison to standard melphalan (39:47)
• Overexpression of Bcl-2 in patients with t(11;14) MM and rationale for the use of venetoclax (41:42)
• Activity and tolerability of anti-B-cell maturation antigen (BCMA) CAR T-cell therapy in patients with MM (45:40)
• Use of a bispecific T-cell engager to target BCMA and CD3 in patients with MM; early efficacy and safety data with AMG 420 (49:55)
• Incidence and management of cytokine release syndrome and neurotoxicity associated with anti-BCMA CAR T-cell therapy for MM (52:39)
• Future directions for CAR T-cell therapy in MM (55:09)

CME information and select publications